Dr. Suzette Sutherland

Right. So we know when we talk to patients about cancer, oftentimes I say the C word before I say the word, right? Because it's so frightening, right? And we as physicians and surgeons know that one person's cancer isn't another person's cancer, especially when we're talking about different organs, right?

But even the case when you're talking about bladder cancer, and we know the earlier you find it, it's totally treatable, right? And when it's late in the diagnosis, it's a whole nother issue for the patients, right? So that's another thing that we're talking about here today, how we can do a better job at detection early. and utilizing some of the newer tools that we have.

But even the case when you're talking about bladder cancer, and we know the earlier you find it, it's totally treatable, right? And when it's late in the diagnosis, it's a whole nother issue for the patients, right? So that's another thing that we're talking about here today, how we can do a better job at detection early. and utilizing some of the newer tools that we have.

But even the case when you're talking about bladder cancer, and we know the earlier you find it, it's totally treatable, right? And when it's late in the diagnosis, it's a whole nother issue for the patients, right? So that's another thing that we're talking about here today, how we can do a better job at detection early. and utilizing some of the newer tools that we have.

Let's look at the AUA guidelines really quickly, right? For the risk stratification, we know it's determined low risk, intermediate high risk, and the things that come into play for that, much of it histological things, and that's where our technology can help us. Can you briefly kind of go into a little bit of the main points that go into our risk stratification today?

Let's look at the AUA guidelines really quickly, right? For the risk stratification, we know it's determined low risk, intermediate high risk, and the things that come into play for that, much of it histological things, and that's where our technology can help us. Can you briefly kind of go into a little bit of the main points that go into our risk stratification today?

Let's look at the AUA guidelines really quickly, right? For the risk stratification, we know it's determined low risk, intermediate high risk, and the things that come into play for that, much of it histological things, and that's where our technology can help us. Can you briefly kind of go into a little bit of the main points that go into our risk stratification today?

Yeah. So it's oh so important to really know the accurate histology, right? At the time of biopsy, at the time of look-see, right? When we take them for a look, cystoscopically, whether it's in the office or in the OR, we want to be really confident that we know what we're seeing, that when we see nothing, as an example, that we really are seeing nothing.

Yeah. So it's oh so important to really know the accurate histology, right? At the time of biopsy, at the time of look-see, right? When we take them for a look, cystoscopically, whether it's in the office or in the OR, we want to be really confident that we know what we're seeing, that when we see nothing, as an example, that we really are seeing nothing.

Yeah. So it's oh so important to really know the accurate histology, right? At the time of biopsy, at the time of look-see, right? When we take them for a look, cystoscopically, whether it's in the office or in the OR, we want to be really confident that we know what we're seeing, that when we see nothing, as an example, that we really are seeing nothing.

So tell us about the blue light cystoscopy, the cyst view, and how that works and how that enhances our visualization. Yes.

So tell us about the blue light cystoscopy, the cyst view, and how that works and how that enhances our visualization. Yes.

So tell us about the blue light cystoscopy, the cyst view, and how that works and how that enhances our visualization. Yes.

I've had the opportunity to use this myself and was really astounded at what I saw on white light versus what I then was able to see on blue light. And so it really was an eye opener. The first time I used it was several years ago, but it really was an eye opener.

I've had the opportunity to use this myself and was really astounded at what I saw on white light versus what I then was able to see on blue light. And so it really was an eye opener. The first time I used it was several years ago, but it really was an eye opener.

I've had the opportunity to use this myself and was really astounded at what I saw on white light versus what I then was able to see on blue light. And so it really was an eye opener. The first time I used it was several years ago, but it really was an eye opener.

And I'm a firm believer that it helps with diagnostics at this point and really that, you know, it should be used if possible on almost all patients. What are your thoughts on that? when it should be used? Or is there a time when it shouldn't be used?

And I'm a firm believer that it helps with diagnostics at this point and really that, you know, it should be used if possible on almost all patients. What are your thoughts on that? when it should be used? Or is there a time when it shouldn't be used?

And I'm a firm believer that it helps with diagnostics at this point and really that, you know, it should be used if possible on almost all patients. What are your thoughts on that? when it should be used? Or is there a time when it shouldn't be used?

So that's a huge number, right? One third of the patients. And we're talking about something as serious as CIS. Exactly.